The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


The Journal of Immunology, 2009, 182, 6494 -6507
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0803350

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by del Fresno, C.
Right arrow Articles by López-Collazo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by del Fresno, C.
Right arrow Articles by López-Collazo, E.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cystic Fibrosis

Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients1

Carlos del Fresno*, Francisco García-Rio{dagger}, Vanesa Gómez-Piña*, Alessandra Soares-Schanoski*, Irene Fernández-Ruíz*, Teresa Jurado*, Tasneem Kajiji{ddagger}, Chen Shu{ddagger}, Elvira Marín§, Ana Gutierrez del Arroyo, Concepción Prados{dagger}, Francisco Arnalich||, Pablo Fuentes-Prior#, Subrha K. Biswas{ddagger} and Eduardo López-Collazo2,*

* Research Unit, Laboratory of Tumor Immunology, and {dagger} Service of Respiratory Diseases, "La Paz" Hospital, Madrid, Spain; {ddagger} Singapore Immunology Network, Biomedical Sciences Institutes, Singapore; § Discovery Unit, EMPIREO Diagnostic, Madrid, Spain; Department of Medicine and Wolfson Institute for Biomedical Research, University College London, London, United Kingdom; || Emergency Service, "La Paz" Hospital, "La Paz" Hospital Medical School, Universidad Autónoma de Madrid, Madrid, Spain; and # Cardiovascular Research Center and Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Monocyte exposure to LPS induces a transient state in which these cells are refractory to further endotoxin stimulation. This phenomenon, termed endotoxin tolerance (ET), is characterized by a decreased production of cytokines in response to the proinflammatory stimulus. We have established a robust model of ET and have determined the time frame and features of LPS unresponsiveness in cultured human monocytes. A large number of genes transcribed in tolerant monocytes were classified as either "tolerizable" or "nontolerizable" depending on their expression levels during the ET phase. Tolerant monocytes exhibit rapid IL-1R-associated kinase-M (IRAK-M) overexpression, high levels of triggering receptor expressed on myeloid cells-1 (TREM-1) and CD64, and a marked down-regulation of MHC molecules and NF-{kappa}B2. These cells combine potent phagocytic activity with impaired capability for Ag presentation. We also show that circulating monocytes isolated from cystic fibrosis patients share all the determinants that characterize cells locked in an ET state. These findings identify a new mechanism that contributes to impaired inflammation in cystic fibrosis patients despite a high frequency of infections. Our results indicate that a tolerant phenotype interferes with timing, efficiency, and outcome of the innate immune responses against bacterial infections.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from "Ministerio de Ciencia e Innovación" (SAF1256 and SAF3290), Fondo Sanitarios de Investigación, and from "Fundación Médica de la Mutua Madrileña de Automovilística" (to E.L.-C.).

2 Address correspondence and reprint requests to Dr. Eduardo López-Collazo, Research Unit, Laboratory of Tumor Immunology, "La Paz" Hospital, 28046 Madrid, Spain. E-mail address: elopezc.hulp{at}salud.madrid.org

3 Abbreviations used in this paper: ET, endotoxin tolerance; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IRAK, IL-1R-associated kinase; Formula , untreated cells; Q-PCR, quantitative PCR; TREM, triggering receptor expressed on myeloid cells; ttol, time of tolerization; trec, time of recovery; tst, time of stimulation.

4 The online version of this article contains supplemental material.




This article has been cited by other articles:


Home page
J. Immunol.Home page
O. Krysko, T. Van Zele, S. Claeys, and C. Bachert
Comment on "Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients"
J. Immunol., October 15, 2009; 183(8): 4831 - 4832.
[Full Text] [PDF]


Home page
J. Immunol.Home page
F. Garcia-Rio, C. del Fresno, P. Fuentes-Prior, and E. Lopez-Collazo
Response to Comment on "Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients"
J. Immunol., October 15, 2009; 183(8): 4831 - 4832.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.